# OnCo record hb-200 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/hb-200/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "hb-200" ;
  schema:name "HB-200"@en ;
  schema:alternateName "HB-201"@en, "HB-202"@en, "Eseba-vec"@en ;
  schema:description "HB-200 is a vaccine built from two harmless engineered viruses that teach the immune system to attack the HPV16 proteins inside cervical and throat cancers. It has been tested with pembrolizumab in HPV16-positive head and neck cancer."@en ;
  schema:url <https://onco.cc/drugs/hb-200/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:status "phase-2" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Arenavirus-vector therapeutic vaccine (HPV16 E6/E7)" ;
  onco:related <https://onco.cc/drugs/pembrolizumab/> ;
  onco:cancers <https://onco.cc/cancers/recurrent-metastatic-hnscc/> ;
  onco:technologies <https://onco.cc/technologies/hpv-vaccine/> ;
  onco:companies <https://onco.cc/companies/hookipa-pharma/> .